

Werfen to acquire Immucor

Nov. 4, 2022—[Werfen](#) announced it has agreed to acquire [Immucor](#) from asset management firm TPG. Werfen said in a press release that the acquisition will allow the company to expand its portfolio of specialized diagnostics solutions for hospitals and clinical laboratories.

“We highly value Immucor’s commitment to enhancing care for all patients in need of a transfusion or transplant,” Marc Rubiralta, president of Werfen, said in the release. “This fits squarely with our long-term vision and strategy, aligns with our focus, and complements Werfen’s values.”

Werfen reported that upon completion of the acquisition and based on 2021 figures, it will surpass €2.2 billion in revenue. The transaction is expected to close during the first half of next year.